Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
20 Maggio 2024 - 4:11PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of May 2024
Commission File Number: 001-41411
Haleon plc
(Translation
of registrant’s name into English)
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
EXHIBIT INDEX
|
Exhibit Number
|
Description
|
|
99.1
|
20
May 2024 - “Holding(s) in Company”
|
99.1
20
May 2024
HALEON PLC
("Haleon" or "the Company")
TR-1: Standard
form for notification of major holdings
|
1a. Identity of the issuer or the underlying issuer of existing
shares to which voting rights are attached ii:
|
Haleon plc
|
|
1b. Please indicate if the issuer is a non-UK issuer
(please mark with an "X"
if appropriate)
|
|
Non-UK issuer
|
|
|
2. Reason for the notification (please
mark the appropriate box or boxes with an "X")
|
|
An acquisition or disposal of voting rights
|
x
|
|
An acquisition or disposal of financial instruments
|
|
|
An event changing the breakdown of voting rights
|
|
|
Other (please specify) iii:
|
|
|
3. Details of person subject to the notification
obligation iv
|
|
Name
|
GSK plc
|
|
City and country of registered office (if applicable)
|
London, England
|
|
4. Full name of shareholder(s) (if
different from 3.) v
|
|
Name
|
Vidacos Nominees Limited
|
|
City and country of registered office (if applicable)
|
London, England
|
|
5. Date on which the threshold was crossed or
reached vi:
|
17/05/2024
|
|
6. Date on which issuer notified (DD/MM/YYYY):
|
20/05/2024
|
|
7. Total positions of person(s) subject to the notification
obligation
|
|
|
% of voting rights attached to shares (total of 8. A)
|
% of voting
rights through financial
instruments(total of 8.B 1 + 8.B 2)
|
Total of both in % (8.A + 8.B)
|
Total number of voting rights held in issuer (8.A +
8.B) vii
|
|
Resulting situation on the date on which threshold was crossed or
reached
|
0
|
0
|
0
|
0
|
|
Position of previous notification (if
applicable)
|
4.17
|
0
|
4.17
|
|
|
|
|
|
|
|
|
|
|
8. Notified details of the resulting situation on the date on which
the threshold was crossed or reached viii
|
|
A: Voting rights attached to shares
|
|
Class/type ofshares
ISIN code (if possible)
|
Number of voting rights ix
|
% of voting rights
|
|
Direct
(DTR5.1)
|
Indirect
(DTR5.2.1)
|
Direct
(DTR5.1)
|
Indirect
(DTR5.2.1)
|
|
GB00BMX86B70
|
0
|
0
|
0
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
SUBTOTAL 8. A
|
0
|
0
|
|
|
|
B 1: Financial Instruments according to DTR5.3.1R (1)
(a)
|
|
Type of financial instrument
|
Expirationdate x
|
Exercise/Conversion Period xi
|
Number of voting rights that may be acquired if the instrument
is
exercised/converted.
|
% of voting rights
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
SUBTOTAL 8. B 1
|
|
|
|
|
|
B 2: Financial Instruments with similar economic effect according
to DTR5.3.1R (1) (b)
|
|
Type of financial instrument
|
Expirationdate x
|
Exercise/Conversion Period xi
|
Physical or cash
Settlement xii
|
Number of voting rights
|
% of voting rights
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
SUBTOTAL 8.B.2
|
|
|
|
9. Information in relation to the person subject to the
notification obligation (please
mark the
applicable box with an "X")
|
|
Person subject to the notification obligation is not controlled by
any natural person or legal entity and does not control any other
undertaking(s) holding directly or indirectly an interest in the
(underlying) issuer xiii
|
|
|
Full chain
of controlled undertakings through which the voting rights and/or
thefinancial instruments are effectively held starting with the
ultimate controlling natural person or legal entity (please
add additional rows as necessary) xiv
|
|
|
Name xv
|
% of voting rights if it equals or is higher than the notifiable
threshold
|
% of voting rights through financial instruments if it equals or is
higher than the notifiable threshold
|
Total of both if it equals or is higher than the notifiable
threshold
|
|
GSK plc (Chain 1)
|
0
|
|
0
|
|
GlaxoSmithKline Holdings Limited (Chain 1)
|
0
|
|
0
|
|
GlaxoSmithKline Finance plc (Chain 1)
|
0
|
|
0
|
|
Glaxo Group Limited (Chain 1)
|
0
|
|
0
|
|
|
|
|
|
|
GSK plc (Chain 2)
|
0
|
|
0
|
|
GSK LP Limited (Chain 2)
|
0
|
|
0
|
|
GSK GP 1 Limited (Chain 2)
|
0
|
|
0
|
|
GSK (No.1) Scottish Limited Partnership (Chain 2)
|
0
|
|
0
|
|
|
|
10. In
case of proxy voting, please identify:
|
|
Name of the proxy holder
|
|
|
The number and % of voting rights held
|
|
|
The date until which the voting rights will be held
|
|
|
|
|
11. Additional information xvi
|
|
This notification relates to the sale by GSK plc (via its
indirectly wholly-owned subsidiaries, GSK (No.1) Scottish Limited
Partnership and Glaxo Group Limited) of the entirety of its
remaining interest in Haleon plc.
GSK GP 1 Limited is the sole general partner of GSK (No.1) Scottish
Limited Partnership. GSK LP Limited is the sole limited
partner of GSK (No.1) Scottish Limited Partnership. Glaxo
Group Limited and GSK (No.1) Scottish Limited Partnership held
their shares in Haleon plc via a custodian, Vidacos Nominees
Limited, which held the legal title to those shares on their behalf
pursuant to a custody arrangement.
|
|
|
|
|
|
|
|
Place of completion
|
London, England
|
|
Date of completion
|
20 May 2024
|
Amanda Mellor, Company Secretary
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
|
HALEON PLC
(Registrant)
|
|
Date:
May 20, 2024
|
By:
|
/s/
Amanda Mellor
|
|
|
|
Name:
|
Amanda
Mellor
|
|
|
|
Title:
|
Company
Secretary
|
Grafico Azioni Haleon (NYSE:HLN)
Storico
Da Feb 2025 a Mar 2025
Grafico Azioni Haleon (NYSE:HLN)
Storico
Da Mar 2024 a Mar 2025
